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Abstract
Background: Salmonella is an infectious agents causing numerous cases of illness each year, and
thereby having significant economic impact. Using returning Swedish travellers we estimated the
burden of salmonellosis in different European countries.
Methods: From the Swedish database on notifiable communicable diseases 15,864 cases with
travel-associated salmonellosis acquired in Europe from 1997–2003 were retrieved. These cases
were compared to a dataset from the same years on 14,171 randomly selected Swedish residents,
with a history of recent overnight travel in Europe. Distribution of salmonellosis in returning
travellers and the distribution of Salmonella Enteritidis was analysed for different member states in
the European Union, associated and candidate countries. The risk of being notified with a
salmonella infection after return from each European country/region was calculated, and compared
with official reporting data rom these countries. Using Norway as reference country, we could 1)
construct comparable incidence estimates and 2) calculate the "under-reporting" in each country
compared to Norway.
Results: The highest burden of salmonellosis was estimated for Bulgaria (2741/100,000), followed
by Turkey with 2344/100 000 and Malta with 2141/100 000. S. Enteritidis is the dominating
serotype, 66.9 % of all cases and phage type 4 accounts for 37.5 % of the S. Enteritidis cases
Conclusion: Using returning tourists as a sentinel population can provide a useful base for
comparison of disease burdens in different countries/regions. Focusing prevention of salmonellosis
to prevention of egg and poultry associated S. Enteritidis infection will have a major impact from a
public health perspective and will significantly lower the burden of disease in most European
countries.
Background
Salmonellosis is an important public health problem
causing substantial morbidity, and thus also having a sig-
nificant economic impact. Although most infections
cause mild to moderate self-limited disease, serious infec-
tions leading to death do occur. In the United States it is
estimated that 1.4 million non-typhoidal Salmonella
infections with 400 deaths occurs annually [1]. Calcula-
tions from England and Wales regarding year 1995
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resulted in an estimate of 102,227 indigenous cases, with
3,412 hospital admissions and 268 deaths [2].
The infective dose is usually high, but the bacteria grow
well in most foodstuff. In food with a high fat content, e.g.
chocolate and cheese, the infective dose is very low, and
just a few bacteria may be sufficient to cause infection
[3,4]. The susceptibility to infection varies; in infants, eld-
erly, or compromised hosts, the critical infective dose is
lower [5]. The onset of disease is often acute with diar-
rhoea, nausea and vomiting [6]. The incubation period is
1–3 (range <1–10) days. The carrier state is normally 4–6
weeks, but a few percent may be asymptomatic carriers for
months or even years [3,7]. No vaccine is available against
non-typhoidal salmonellosis. Using the Kauffmann-
White scheme for antisera reaction to different bacterial O
and H antigens, more than 2,500 Salmonella serovars have
been identified, with prevalence patterns varying between
different parts of the world [8,9]. In Europe S. Enteritidis
has been the most reported serovar since the middle of the
1980s [10]. In the developed world salmonellosis due to
S. Enteritidis is most often associated with consumption
of poultry and eggs [11,12].
The European Union (EU) consists of 25 member states
along with 4 associated EEA/ EFTA (European Economic
Area/ European Free Trade Area) countries and 4 candi-
date countries, with altogether 630 millions inhabitants.
The recent establishment of the European Centre for Dis-
ease Prevention and Control (ECDC), shows that control
and prevention of communicable diseases are high on the
EU political agenda. The Salmonella species is one of the
eight micro-organisms in the EU Zoonoses Monitoring
Directive (2003/99/EG), which is mandatory to always
monitor [13]. The subject matter and scope of this direc-
tive is to ensure that zoonoses are properly monitored and
that foodborne outbreaks receive proper epidemiological
investigation, to enable the collection in the EU of the rel-
evant information necessary to evaluate trends and
sources. In the Zoonosis Control Regulation (2160/2003)
which regulates the control of salmonella and other spec-
ified foodborne zoonotic agents, salmonella is the only
agent specified [14]. This directive and regulations shows
that salmonellosis is a disease considered to have a high
impact on the human health in the EU. However, public
health actions need to be based on best possible surveil-
lance data, but the ability to detect and report enteric
zoonoses varies considerably between the European
countries, hampering meaningful comparisons between
countries [15].
In this study we are using Swedish notification data on all
cases of salmonellosis, who acquired the infection during
travel in Europe, and a unique database on travel patterns
to give an estimate of the comparative burden of non-
typhoidal salmonellosis in different European countries.
Methods
Notification data on salmonellosis
The statutory notification of salmonellosis in Sweden is
regulated in the Communicable Disease Act. All notifica-
tions are submitted to the Swedish Institute for Infectious
Disease Control (SMI), both by the physician having seen
the patient (clinical notification) and by the laboratory
having diagnosed the causative agent (laboratory notifica-
tion). The clinical notifications include information of
epidemiological relevance, e.g. route of infection, risk
group, and likely place and country of infection. The lab-
oratory notifications include the Salmonella serovar and if
a  S. Enteritidis or S. Typhimurium, phage types are
included. The clinical and laboratory reports for each
patient are merged, using a unique personal identification
number. The personal identification number is used in all
contacts with the health care, both private and public.
For this study, notification data for the period January
1997 to December 2003 were used. All records in the
national surveillance database concerning patients noti-
fied with salmonellosis were retrieved. The clinical notifi-
cation has the information in which country the patient
has acquired the infection and this information was used
to judge if the patient was a case of travel associated sal-
monellosis or not. Patients with stated indigenously
acquired infection (i.e. infected in Sweden) or patients for
which information on likely country of infection was
either missing or "unknown" were excluded. Also patients
with a travel history outside Europe were excluded. Fur-
thermore, the dataset was "cleaned" from infections in
recently arrived immigrants, refugees and non-Swedish
visitors (identified through the personal identification
number).
Travel patterns
As denominator on travel patterns, a commercial data-
base, the Tourist Database (TDB) was used [16]. This data-
set is based on a randomized selection of 2,000 persons of
the Swedish population every month. These persons are
telephone interviewed with questions on both business
and pleasure travel during last month, and the data
weighted and extrapolated to give an estimate of the total
number of Swedish travellers to different destinations.
Out of the total database, containing data on almost
170,000 interviews, altogether 14,171 records from
respondents with a history of recent overnight travel in
Europe were extracted. These 14,171records represents all
persons in the TBD, which has been travelling in Europe.
Data on country/region of travel was used for analysis. No
data on any illness is available from this dataset.BMC Public Health 2006, 6:4 http://www.biomedcentral.com/1471-2458/6/4
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Serovar typing and phage typing
Serovar typing of the Salmonella strains was performed by
agglutination using antiserum from Reagensia, Stock-
holm, Sweden. Interpretation of serovars was made
according to the latest edition of the Kauffmann-White
scheme from the WHO International Reference Labora-
tory [8]. Phage typing of S. Enteritidis was performed
according to the Colindale scheme [17]. These results
were included in the laboratory notification from the
Swedish national salmonella reference laboratory.
Statistical methods
The risk of disease per 100,000 travellers was calculated
using salmonellosis notification data from the actual
country/region as numerator and the estimated total
numbers of travellers from the TDB as denominator. Data
for each country on the reported number of salmonellosis
cases were retrieved from WHO Surveillance Program for
Control of Foodborne Infections and Intoxications in
Europe, 8th report, year 2000, if not other source is stated.
An under-detection index was calculated with Norway as
the reference country (the country with the lowest risk of
salmonellosis per 100 000 Swedish travellers, and a good
national reporting system). The under-detection index is
calculated by dividing the incidence/100 000 inhabitants
in the country with the risk/100 000 Swedish travellers
who visited the country and this quotient is then dived
with the quotient from the reference country (Norway).
This index denotes estimated number of salmonellosis
cases not notified for every notified case. To measure the
burden of salmonellosis in each country this index was
multiplied with the reported incidence from the actual
country. The method, with a detailed discussion on
strengths and limitations has been previously published
[15].
Ethical considerations
The TDB contains aggregated data only. Notification data
is regulated by the Communicable Disease Act, and con-
tain full personal identification. The subset of the notifi-
Table 1: Comparison of risk of Salmonella infection in Swedish travellers to national reported incidence and estimated incidence of 
salmonellosis.
Country Risk per 100,000 
travellers (95% 
CI)
Percent S. 
Enteritidis 
among Swedish 
travellers
Percent S. 
Typhimurium 
among Swedish 
travellers
Reported 
incidence per 
100,000 
inhabitant
Under-
detection index
Estimated 
incidence per 
100,000 
inhabitant
Norway 0.2 (0.11–0.38) 30 40 3.77 1.0 (ref.) 4
Finland 0.4 (0.28–0.58) 29 39 13.1 0.6 8
Iceland 2.2 (0.79–6.1) 25 75 129 0.4 47
Estonia1 2.6 (0.94–7.2) 85 2 40.6 1.3 54
Ireland 3.2 (1.8–3.8) 33 25 16.0 4.3 69
Denmark 3.8 (3.4–4.3 67 15 44.4 1.8 81
Netherlands2 4.6 (3.2–6.6) 71 29 12.6 7.7 98
United Kingdom 5.6 (4.8–6.5) 83 7 27.9 4.3 119
France 8.4 (7.2–9.7) 59 13 21.5 8.3 178
Germany 8.3 (7.4–9.3) 79 13 96.1 1.8 177
Austria 12.0 (9.7–14.9) 83 2 85.6 3.0 255
Italy 12.8 (11.2–14.6) 54 18 20.6 13.1 271
Belgium 13.5 (10.0–18.2) 86 10 153 1.9 286
Lithuania1 15.3 (4.5–52.5) 94 0 32.5 10.0 325
Latvia1 23.9 (12.4–46.5) 98 1 43.4 11.7 507
Greece 39.2 (36.4–42.2) 70 8 8.5 97.7 833
Croatia 40.1 (32.7–49.1) 85 8 27.9 30.6 852
Slovenia 40.1 (32.7–49.1) 50 20 85.1 10.0 852
Hungary 41.8 (33.7–51.8) 71 34 163 5.5 888
Czech Republic 54.8 (45.5–66.1) 77 5 391 3.0 1161
Slovakia 54.8 (45.5–66.1) 94 0 336 3.5 1165
Cyprus 66.0 (56.2–77.6) 37 15 19.7 71.2 1403
Romania 68.6 (39.5–119) 40 31 4.4 332 1457
Spain3 72.0 (68.5–75.7) 79 7 14.9 103 1531
Poland 76.5 (65.5–89.4) 77 3 100 16.2 1626
Portugal 79.9 (68.0–93.9) 82 7 4.49 378 1697
Malta 101 (69.1–147) 60 13 23.1 92.6 2141
Turkey 110 (97.2–125) 48 4 39.2 59.8 2344
Bulgaria 129 (103–162) 68 17 10.1 271 2741
1 Risk per 100,000 travellers calculated on figures from 2002–2003
2 Incidence calculated on 63% of inhabitants since reported number of cases is from laboratories with a catchments area of 63% of inhabitantsB
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Table 2: The number per country of the most common Salmonella serovars from notified cases in returning Swedish travellers with non-typhoidal salmonellosis 1997–2003.
Salmonella serovars
Country Agona Blockley Enteritidis Hadar Heidelberg Infantis Montevideo Newport Saintpaul Typhimurium Virchow
Norway 3 4
Finland 8 1 1 11 1
Denmark 2 239 4 1 15 2 3 1 53 4
Iceland 1 3
Belgium 1 60 2 7
United Kingdom 1 173 1 41
France 1 3 149 5 2 2 5 2 32 9
Ireland 4 3
Netherlands 25 10
Switzerland 7
Germany 1 323 3 1 7 1 1 53 5
Austria 1 101 1 1 2
Italy 3 184 1 4 5 3 4 60 2
Malta 5 2 78 4 7 17 3
Portugal 1 4 498 11 2 4 42 4
Spain 14 3 4,891 100 16 17 16 34 6 446 78
Greece 8 31 1,315 39 11 23 19 21 2 156 36
Baltic countries 143 1 1 1
Bulgaria 10 350 5 3 3 4 1 90
Poland 1 510 49 4 1 2 4 18 4
Romania 19 2 15
Czech Rep. + Slovakia 5 290 1 1 8 4 16
Hungary 2 7 164 16 5 14 8 5
Cyprus 2 80 202 26 10 17 3 1 1 81 20
Turkey 94 6 674 17 1 6 17 4 58 210
Total 147 143 10,637 289 52 121 63 79 41 1,203 383BMC Public Health 2006, 6:4 http://www.biomedcentral.com/1471-2458/6/4
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cation database extracted for this study does not contain
any information that could be linked to a specific person.
The Ethical Committee of the Karolinska Institute, Stock-
holm, Sweden, approved the study.
Results
Travel pattern
Data from the 14,171 respondents in the TDB with recent
overnight travel to different European countries/regions
during the study period 1997–2003 were weighted and
projected to give an estimate of the number of journeys to
each European country/region. According to these esti-
mates, Swedish travellers did approximately 60 million
overnight journeys to other European countries (78% lei-
sure trips and 22% business trips) during the period.
Salmonellosis in returning travellers
For the study period 1997–2003, altogether 15,864
patients were notified with a salmonella infection after a
journey in Europe and out of them 10,607 had an infec-
tion caused by S. Enteritidis. No cases of salmonellosis
were reported among travellers from Luxembourg and
Liechtenstein.
The total risk of being notified with salmonellosis was
26.2/100,000 travellers. The lowest risk was seen after a
journey to Norway (0.2/100,000 travellers) followed by
Finland (0.4/100,000 travellers) and Norway was hence
used as reference. The highest risks was observed in travel-
lers returning from Bulgaria (129/100,000 travellers), Tur-
key (110/100,000 travellers and Malta (101/100,000
travellers) (Table 1).
The total risk of being notified with a salmonella infection
caused by S. Enteritidis, all phage types, was 17.5/100,000
travellers. The highest risks were seen for traveling in Bul-
garia with 87.5/ 100,000 travellers, Portugal 66.4/
100,000 travellers, and Turkey 53/100,000 travellers, data
not shown.
Disease burden
When using our data to estimate the actual incidence of
salmonellosis, the incidence varied from 4/100,000
inhabitants in Norway up to 2,741/100,000 inhabitants
in Bulgaria (Table 1). Countries with the lowest burden of
disease were situated in the northern parts of Europe
while countries with a higher burden were situated in the
southern parts of Europe. Poland is the only country in
the northern part that had a high burden of disease. Coun-
tries in the eastern parts of Europe also tended to have a
higher burden than the countries situated in the western
parts of Europe.
Serovar distribution
Details on the different serovars of Salmonella, clearly
showed the relative high burden of S. Enteritidis in
Europe, accounting for 67% of the cases. However, the
proportion of S. Enteritidis cases from the different coun-
tries varied from 25% (Iceland) up to 98% (Latvia). The
second most frequent serovar was S. Typhimurium
accounting for 9% of the cases (Table 2). When plotting
the proportion of S. Enteritidis in returning travellers
against the estimated incidence no correlation could be
detected (Figure 1).
Phage type distribution of S. Enteritidis
Of the 10,607 cases of S. Enteritidis in our database, data
on phage type (PT) was available for 10,479 (99%) cases.
In all, 48 different phage types were represented among
the notified cases during the study period. Regional varia-
tions in serovar distribution could be noted. S. Enteritidis
PT 4 is the most dominating phage type, accounting for
35% of all S. Enteritidis cases, while PT 1 accounts for
22%. On the Iberian Peninsula and in some eastern parts
of Europe PT 1 is the dominating phage type, while PT
14b is dominating in Greece and PT 8 in Czech Republic,
Denmark and Slovakia, (Table 3). Spain is the only Euro-
pean country having persons returning with PT 44 (28
cases). An outbreak with PT 34 in Denmark caused 73
cases and this phage type is also reported from Spanish
travellers.
Duration of stay
In the TBD the duration of stay is measured in number of
night spent abroad. Figure 4 shows the percentage of night
spent in each country. There are differences in the dura-
tion of stay, which is correlated to the distance to each
country and the accessibility. The duration of stay is not
Proportion of Salmonella Enteritidis in returning travellers,  plotted against the estimated incidence of salmonellosis Figure 1
Proportion of Salmonella Enteritidis in returning 
travellers, plotted against the estimated incidence of 
salmonellosis. Proportion of Salmonella Enteritidis in 
returning travellers, plotted against the estimated incidence 
of salmonellosis. Each dot represents one country in the 
study.
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available in the notification from the physician seeing the
case of salmonellosis.
Discussion
To measure the burden of non-typhoidal salmonellosis in
different countries using the reported cases in each coun-
try will not produce comparable numbers, since the
reporting systems in the different European countries are
very disparate. In some countries all cases are reported,
while in some other countries just the hospitalized cases.
Furthermore, in many countries indigenous and imported
cases are not considered separately.
To get comparable data, we used a different approach,
basing our estimates on returning travellers to Sweden.
Reliable denominator data on travel are essential when
using travel-related disease data for calculations of risks
[18]. The TDB database gives information on each coun-
try/region visited with at least one overnight stay (with
information obtained directly from the travellers), provid-
ing us with a unique opportunity to relate surveillance
data to a better-suited travel denominator when calculat-
ing the burden of salmonellosis in European countries.
This database has previously been used for estimating the
risk of travel-related diseases in various parts of the world
[9,19-23], and the strengths and limitations of using this
approach has been discussed in detail in these articles.
As the numerator we used the notifications in the national
surveillance system. Since Sweden has a uniform national
system for reporting infectious diseases and the notifica-
tion database rests on both clinical and laboratory notifi-
cations, the sensitivity of the notification system is
comparatively good. Using the capture-recapture tech-
nique to estimate the proportion of cases being reported
by either clinicians or laboratories, more than 99 percent
of all diagnosed Salmonella infections were found to be
reported each year in 1998 to 2002 [24]. Even with a good
notification system, the reported cases likely only repre-
sent the tip of the iceberg. Salmonellosis is an acute,
mostly self-limited disease, and most cases never come
under the attention of a physician, and even less are
microbiologically investigated. This however, should not
in any major way affect how the countries in this study
compare to each other.
The data presented in this study are based on Swedish
travellers and their behaviours and risks could never be
Table 3: The number per country of the most common Salmonella Enteritidis phage types in returning Swedish travellers with non-
typhoidal salmonellosis 1997–2003.
Phage types
Country 1 4 6 6a 6b 8 13a 14b 21
Norway 2
Finland 5 2 1
Denmark 6 23 52 2 61 2 7
Iceland 1
Belgium 2 34 5 6 10
United Kingdom 10 110 14 6 5 4 3 3
France 8 75 12 8 1 18 3
Ireland 4
Netherlands 18 2 1 1 2
Switzerland 5 2
Germany 10 196 25 9 37 1 4 20
Austria 1 46 4 35 4 1 2
Italy 24 75 3 2 24 2 20 14
Malta 18 58 1 1
Portugal 201 96 8 46 2 39 25
Spain 1,689 1,612 128 211 11 86 20 76 151
Greece 139 328 4 120 36 24 3 380 73
Baltic countries 77 20 7 2 9
Bulgaria 7 191 2 2 1 26 15 39 36
Poland 43 183 65 2 1 101 1 84
Rumania 2 9 1 1 1 1
Czech Republic + Slovakia 6 33 12 1 206 5 2 11
Hungary 4 73 30 34 1 5 1
Cyprus 79 71 2 2 1 7 1
Turkey 20 377 73 8 3 2 52
Total 2,263 3,713 450 489 54 694 69 588 519BMC Public Health 2006, 6:4 http://www.biomedcentral.com/1471-2458/6/4
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fully representative for those of the native population in
the respective countries. The risk estimates are also biased
towards the parts of the countries with most tourists.
However, since the data concerning the different countries
are based on the same methods, we believe the risks esti-
mates for the countries from this study are more suited for
comparisons than the reported national incidence figures
from the notification systems – with different structures
and quality. Furthermore, a study from the UK estimated
the incidence of salmonellosis presenting to general prac-
titioners in 1995 to 157 per 100,000 and the incidence of
laboratory confirmed cases to 80 per 100,000 [25], figures
in the same magnitude as our estimate of 119 per 100,000
in that country.
In this study certain countries in Europe stood out as hav-
ing a comparatively very high burden of non-typhoidal
salmonellosis. A north-south gradient could be clearly
distinguished, with increasing incidences the more south
in Europe the country is situated. Also a west-east gradient
is shown with a higher burden in eastern countries/
regions. Being the most common serovar in most regions
of the world, S. Enteritidis is especially dominating in
Europe, where almost 67% of all salmonellosis were due
to this serovar. In Africa, Asia and America, this serovar
has been less dominating and the variety of circulating
serovars greater [9].
The duration of travel may affect the risk per 100,000 trav-
ellers since persons going to southern countries are mostly
on a leisure trip with a longer duration compared to trips
to neighbouring countries and thereby the risk for these
southern countries could be overestimated. In this study
the 4 countries with the highest burden of non-typhoidal
salmonellosis were tourist destinations where Swedish
travellers mostly stay 1–2 weeks. However, the country
with the fifth highest burden, Poland, had travel dura-
tions similar to other neighbouring countries of Sweden.
This indicates that our method is useful, but improve-
ments can be introduced if duration of stay for the
infected traveller is obtainable.
The sometimes very large differences between the esti-
mated disease burden from this study, and the reported
figures from the single countries are problematic from
public health point of view, therefore the strategy on the
future European-level surveillance presented by the ECDC
Table 4: Duration of travel shown as percentage of nights spent in each country
Number of nights
C o u n t r y 1234567 8 9 1 01 1 – 1 7 1 8 – 2 4 > 2 4
Norway 23 20 14 14 6 7 5 1 2 1 4 1 1
F i n l a n d 3 5 2 5 95434 2 1 2 5 2 1
I c e l a n d 0 62 681 58 74 90 1 2 5 1
E s t o n i a 1 4 4 4 1 3 5418 2 2 2 3 1 1
I r e l a n d 6 9 1 71 51 21 81 13 0 3 5 1 1
D e n m a r k 3 1 3 0 1 5 7544 1 1 1 2 1 1
N e t h e r l a n d s 2 12 31 61 5 5 6 12 3 1 5 2 1
United Kingdom 8 17 21 16 9 7 6 3 2 2 6 2 2
F r a n c e 67997 1 1 1 4 6 1 5 1 6 4 3
G e r m a n y 2 1 2 7 1 9 9653 2 1 1 5 1 1
A u s t r i a 3395 1 0 1 2 2 1 8 6 7 1 1 2 2
Italy 1 12 11 6 5 12 13 5 3 4 20 4 3
B e l g i u m 2 61 81 71 5 5 4 83 1 1 2 1 1
Lithuania 2 25 35 18 13 4 0 0 0 2 0 0 2
L a t v i a 2 2 62 42 11 7 2 31 1 1 2 0 0
G r e e c e 01112 2 3 3 8 2 1 1 2 9 2 1
S l o v e n i a 0480400 4 0 0 4 2 1 5 2 3
Hungary 1 11 16 15 11 5 7 3 1 3 10 8 9
Czech Republic 1 9 27 26 12 10 6 2 1 3 2 0 0
S l o v a k i a 1 4 2 1 00007 7 0 7 0 0 4 3
C y p r u s 00002 2 1 4 9 1 1 0 2 4 1 2
R o m a n i a 44545 2 2 2 9 4 1 2 1 7 1 2
S p a i n 12332 2 0 3 2 3 2 2 2 3 3 3
P o l a n d 1 6 2 7 1 3 9827 2 3 3 6 1 1
P o r t u g a l 52646 2 3 2 9 4 0 2 1 7 1 2
M a l t a 00636 2 5 2 8 3 2 0 5 2 2 2
T u r k e y 00431 2 1 3 0 2 0 1 3 3 3 2
B u l g a r i a 00610 2 2 4 0 5 0 0 2 5 1 2BMC Public Health 2006, 6:4 http://www.biomedcentral.com/1471-2458/6/4
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in October emphasized the needs for more comparable
surveillance data,.
Due to very rigorous control methods in the agricultural
area, Sweden has an extremely low domestic incidence of
salmonellosis in humans and well as in animals [26,27];
less than 0.1 % of food-producing animals are found to
carry Salmonella [26]. This favourable situation is shared
with the EU member state Finland and the associated
countries Iceland and Norway. These four countries have
also managed to keep free from the pandemic of egg-asso-
ciated S. Enteritidis that is contributing to a great extent to
the burden of salmonellosis in other European countries.
At least 75% of all notified episodes of salmonellosis in
Sweden are travel-related. Even in neighbouring Den-
mark, the situation is the reversed, with only 25% of the
most common serovar, S. Enteritidis being related to
travel [28]. When becoming members of the EU, Sweden
together with Finland received specific Salmonella guaran-
tees, which states that fresh beef, veal and pig meat
together with poultry meat should be tested for the pres-
ence of Salmonella bacteria before importation. If any
serovar of Salmonella is found, importation is not allowed.
These guarantees have contributed to the maintenance of
the excellent Salmonella situation in these member states
and other states may apply for similar guarantees when
they have approved control programmes in the agricul-
tural area. Our study shows that these guarantees have a
positive effect on public health, resulting in a very low
level of indigenous cases of salmonellosis.
The two most common serovars, S. Enteritidis and S.
Typhimurium, are well known to have different animals
as reservoir for the disease in Europe. S. Enteritidis is
shown to be the most frequent serovar isolated from poul-
try and poultry products including table eggs, while S.
Typhimurium is the most frequent serovar in pigs, pork,
beef and veal. In cattle S. Dublin is the most frequent iso-
lated serovar but S. Typhimurium is the next frequent
serovar. [29]. However, S. Typhimurium is also rather
common in poultry and S. Enteritidis is isolated from beef
and pork.
Conclusion
Our data shows that focusing prevention of salmonellosis
to prevention of S. Enteritidis infection will have a major
impact from a public health perspective and will signifi-
cantly lower the burden of salmonellosis in most Euro-
pean countries. S. Enteritidis is well known to originate
from poultry products and products prepared with raw
shell eggs. Aiming at reducing the presence of S. Enteri-
tidis in poultry products and eggs will have a positive side-
effect since not only S. Enteritidis will be reduced but also
other serotypes of Salmonella present in these products
resulting in an even lower burden of salmonellosis in
Europe. However, since there was no direct correlation
between the proportion of S. Enteritidis and the estimated
overall incidence of salmonellosis, also other actions than
those directed against infected poultry and eggs are
needed to get down the burden of salmonellosis in those
countries with the highest incidence. The new ECDC has
identified zoonoses as one of its main priorities, and will
together with the EU Member States, the European Com-
mission and the European Food Safety Agency (EFSA)
play a pivotal role in the future actions against salmonel-
losis in Europe.
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